Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice
- 14 March 2017
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 77 (6) , 1250-1260
Abstract
Accurate assessment of TP53 gene status in sporadic tumors and in the germline of individuals at high risk of cancer due to Li–Fraumeni Syndrome (LFS) has important clinical implications for diagnosis, surveillance, and therapy. Genomic data from more than 20,000 cancer genomes provide a wealth of information on cancer gene alterations and have confirmed TP53 as the most commonly mutated gene in human cancer. Analysis of a database of 70,000 TP53 variants reveals that the two newly discovered exons of the gene, exons 9β and 9γ, generated by alternative splicing, are the targets of inactivating mutation events in breast, liver, and head and neck tumors. Furthermore, germline rearrange-ments in intron 1 of TP53 are associated with LFS and are frequently observed in sporadic osteosarcoma. In this context of constantly growing genomic data, we discuss how screening strategies must be improved when assessing TP53 status in clinical samples. Finally, we discuss how TP53 alterations should be described by using accurate nomenclature to avoid confusion in scientific and clinical reports. Cancer Res; 77(6); 1250–60. ©2017 AACR.Keywords
All Related Versions
This publication has 86 references indexed in Scilit:
- A germline variant in the TP53 polyadenylation signal confers cancer susceptibilityNature Genetics, 2011
- Biological functions of p53 isoforms through evolution: lessons from animal and cellular modelsCell Death & Differentiation, 2011
- Mutant p53 Gain-of-Function in CancerCold Spring Harbor Perspectives in Biology, 2009
- Clinical Outcomes and Correlates of TP53 Mutations and CancerCold Spring Harbor Perspectives in Biology, 2009
- TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical UseCold Spring Harbor Perspectives in Biology, 2009
- Cytoplasmic functions of the tumour suppressor p53Nature, 2009
- Impact of mutant p53 functional properties onTP53mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 databaseHuman Mutation, 2007
- Restoration of p53 function leads to tumour regression in vivoNature, 2007
- An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinomaProceedings of the National Academy of Sciences, 2001
- Mutations in the p53 gene occur in diverse human tumour typesNature, 1989